Contribute to the future of psilocybin therapy research
Health research is important because it tells us about what works best. Health care professionals and health system decision-makers use health research for many reasons, including but not limited to:
- Making advances and improvements in tests and diagnoses, treatments, medicines, and devices.
- Informing the way health care services are delivered.
Health research is also important to patients and their families; helping them make informed decisions about their care plan.
A team of clinicians and end-of-life specialists; alongside partners from Victoria Hospice, TheraPsil, and the psychedelic medicine assisted therapy community, are interested in generating evidence that explores the use of psilocybin in the compassionate treatment of end-of-life emotional distress.
We want to listen and learn from patients to ensure future research activities reflect patient priorities and interests.
If you have received or are considering receiving psilocybin-assisted therapy for end-of-life distress, we want to hear from you!
What do you think are important topics related to Psilocybin-Assisted Therapy and end-of-life emotional distress that researchers should generate evidence on next? This is your opportunity to share your story and chart the future of psilocybin-assisted therapy!
*Prior knowledge about health research is not required.
The Current Research
“Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life.”
Ross et al. 2016
“Psilocybin produced large and significant decreases in clinician-rated and self-rated measures of depression, anxiety or mood disturbance, and increases in measures of quality of life, life meaning, death acceptance, and optimism. These effects were sustained at 6 months.”
Griffiths et al. 2016
We have developed a comprehensive reading list of original scientific research papers from the past decade relating to psilocybin-assisted psychotherapy in the treatment of end-of-life distress.
The items in this bibliography collectively document that more than 2000 doses of psilocybin have been safely administered since the early ‘90s.
Collectively, they indicate that psilocybin-assisted psychotherapy is an effective and low-risk treatment for end-of-life distress when conducted according to research-established protocols by suitably trained therapists.